REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ --
Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their proprietary hyper-sweet protein,
sweelin®, on blood glucose and insulin levels in humans.